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Open access unand the mass was removed intact. No staging was performed. Final pa-
thology showed an ovarian small-cell carcinoma, hypercalcemic typeBackground
Ovarian small-cell carcinoma of the hypercalcemic type is a rare
neoplasm that typically occurs in young females, with an average
age at diagnosis of 23.9 years (Young et al., 1994, 2010). Patients typ-
ically present with advanced stage disease with a 5-year overall sur-
vival of 10% (Dykgraaf et al., 2009). There is currently no standard
protocol for managing this rare type of carcinoma. However, a previ-
ous report by Senekjian et al. (1989) demonstrated response rates
with a chemotherapy regimen including vinblastine, cisplatin, cyclo-
phosphamide, bleomycin, doxorubicin and etoposide (VPCBAE). The
current report presents a case series of three patients with clinical
stage I ovarian small-cell carcinoma of the hypercalcemic type treated
with unilateral salpingo-oophorectomy followed by six cycles of che-
motherapy with VPCBAE.f Gynecologic Oncology, Unit 1362, The
nter, 1515 Holcombe Blvd., Houston, TX
rg (K.M. Schmeler).
der CC BY-NC-ND license .Case 1
A24 year-old nulligravidwomanwasnoted to have a pelvicmass on
physical examination. Transvaginal sonography and a computed to-
mography (CT) scan conﬁrmed a solid left adnexal mass. She under-
went an exploratory laparotomy and was noted to have a 16 cm left
ovarian necrotic mass with no evidence of extra-ovarian disease. A left
salpingo-oophorectomy (LSO) and pelvic washings were performed
(Fig. 1). She received 6 cycles of VPCBAE combination chemotherapy
at the following doses: vinblastine (6 mg/m2 intravenous (IV) over 30
minutes on Day 1), cisplatin (90 mg/m2 IV over 4 hours on Day 1), cy-
clophosphamide (1000 mg/m2 IV over 60 minutes on Day 2), bleomy-
cin (15 units/m2 IV over 24 hours on Day 2), doxorubicin (45 mg/m2
IV over 30 minutes on Day 3), and etoposide (200 mg/m2 IV over 2
hours on Day 3). All chemotherapy was given on an inpatient basis,
and pegﬁlgrastim 6 mg was administered following each cycle for the
prevention of chemotherapy-induced neutropenia. Prior to initiating
treatment, an echocardiogram and pulmonary function tests (PFTs)
were obtained and found to be normal.
She tolerated the ﬁrst ﬁve cycles of VPCBAE without difﬁculty.
However, she experienced pancytopenia, cellulitis, and signiﬁcant
mucositis following her sixth cycle of treatment. She received blood
and platelet transfusions and was treated with broad-spectrum anti-
biotics. She recovered from these complications without long-term
sequelae. Of note, she resumed normal menses following completion
of chemotherapy. The patient is currently without evidence of disease
33 months after completing treatment.Case 2
A 28 year-old woman (gravida 1, para 1) presented with abdomi-
nal pain. CT scan revealed a 17 x 22 cm ovarian mass. She underwent
an exploratory laparotomy and was noted to have a ruptured left ad-
nexal mass and an inﬂamed retrocecal appendix. There was no
Fig. 1. Small cell carcinoma of the ovary, hypercalcemic type. Panel A: 20× magniﬁca-
tion; small cell carcinoma of the ovary, hypercalcemic type, is characterized by rela-
tively monomorphic cells with scant cytoplasm arranged in sheets with frequent
mitoses (arrows). Panel B: 4× magniﬁcation; follicle-like spaces that interrupt a
sheet-like arrangement of cells (arrows) are noted in up to 80% of cases.
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tomy. Final pathology revealed a small cell carcinoma of the ovary,
hypercalcemic type. The appendix showed no evidence of disease.
She was dispositioned to 6 cycles of VPCBAE chemotherapy with the
same dosing as noted in Case 1. Pegﬁlgrastim 6 mg was administered
following each cycle.
Following her third cycle of chemotherapy, the patientwas hospital-
ized for severe nausea, vomiting, pancytopenia and neutropenic fever.
Blood cultures revealed group A beta-hemolytic streptococcocal bacter-
emia. During her hospitalization, she also developed acute renal insufﬁ-
ciency with a peak creatinine of 3.3 mg/dL that normalized with
hydration. She was treated with antibiotics and underwent blood and
platelet transfusions. The following dose reductions were performed
for subsequent cycles of chemotherapy: cisplatin was reduced by 50%
(45 mg/m2), cyclophosphamide by 25% (750 mg/m2), doxorubicin by
33% (30 mg/m2), and etoposide by 50% (100 mg/m2). Following cycle
#4 of chemotherapy, the patient's PFTs showed a decrease in DLCO and
her bleomycin was therefore held for cycles #5 and #6. She tolerated
the remaining cycles of chemotherapy without side effect or incident.
After completion of chemotherapy, imaging showed no evidence
of disease. Given that the patient was no longer interested in future
fertility and the potential risk for recurrence, the patient subsequently
underwent a robotic hysterectomy, RSO, and omental and peritoneal
biopsies. Final pathology showed no evidence of disease. Of note, the
patient had resumed ovarian function following chemotherapy prior
to undergoing surgery. The patient is currently without evidence of
disease 16 months following completion of therapy. However, she
did experience residual neurologic sequelae after concluding treat-
ment, with peripheral sensory and motor neuropathy with numbness
and tingling in her upper and lower extremities with loss of coordina-
tion in her hands and difﬁculty with ambulation. Gabapentin has been
initiated; she has since had signiﬁcant improvement in her symptoms.
Case 3
A 26 year-old nulligravid woman presented with abdominal pain
and was found to have a 15 cm right adnexal mass on CT scan. She
underwent exploratory laparotomy and right salpingo-oophorectomy.
Final pathology showed a small cell carcinoma of the ovary, hypercalce-
mic type. She received 6 cycles of VPCBAE chemotherapywith the same
dosing as described in the ﬁrst two cases. Pegﬁlgrastim 6 mg was ad-
ministered following each cycle. The patient was admitted to the hospi-
tal following cycle #1 and cycle #5 with neutropenic fever. She was
treated with broad-spectrum antibiotics and recovered quickly. Allcultures were negative. No chemotherapy dose adjustments were
made. Imaging performed 1 month after the completion of chemo-
therapy showed no evidence of disease.
Discussion
We report three cases of ovarian small-cell carcinoma of the hyper-
calcemic type treated with unilateral salpingo-oophorectomy followed
by six cycles of VPCBAE chemotherapy. All patients are without evi-
dence of disease 33, 16 and 1 month following completion of therapy.
The VPCBAE regimen has been shown by Senekjian et al. (1989) to
be effective in prolonging survival in patients with early-stage disease.
In that series, ﬁve cases were described, with patient ages ranging
from 17 to 31 years. Four patients died 11–18 months following initial
laparotomy, and one patient was alive and disease-free at 29 months.
The two longest-surviving patients had stage IA disease.Major reported
toxicities included severe myelosuppression, neutropenic fever, and
polyneuropathy. A subsequent report by Tewari et al. (1997) used the
same regimen for a woman with stage IIIC disease diagnosed during
pregnancy and demonstrated a 5.5-year disease-free interval. Toxicities
included severe myelosuppression, moderate-to-severe nausea and
vomiting, and one episode of neutropenic sepsis. However, she com-
pleted all six courses of chemotherapy and fully recovered from all
aforementioned toxicities.
The regimen administered for the three patients in our series is the
same as that previously reported in the literature. However, in prior re-
ports, chemotherapeutic agents were omitted secondary to dose-
limiting myelosuppression (Senekjian et al., 1989; Tewari et al., 1997).
In our series, all three patients sustained severe myelosuppression,
but all were treated with colony stimulating growth factors and sup-
portive measures such as transfusion of blood products. In Case 2,
after the myelosuppressive episode following the third cycle of
VPCBAE, dosages of cisplatin, cyclophosphamide, doxorubicin, and eto-
poside were reduced, permitting the patient to continue therapy with-
out severe bone marrow toxicity. This dose modiﬁcation strategy was
effective as an alternative to discontinuing VPCBAE due to signiﬁcant
hematologic toxicity. In addition, the known myelosuppressive burden
of this regimen merits primary prophylaxis with a colony-stimulating
growth factor after each cycle of VPCBAE to prevent neutropenic fever.
The Gynecologic Cancer Intergroup recently reported a case series
of 17 patients with this disease (Harrison et al., 2006). Although no
consistent chemo- or radiotherapeutic regimens were reported, the
authors concluded that both radiation therapy and cisplatin-based
combination chemotherapy were shown to improve disease-free sur-
vival. Of the patients with stage I tumors, median survival had not yet
been reached, with 7 of 10 still alive at the time of publication. In con-
trast, the median survival of patients with advanced disease was only
6 months.
Of note, the two patients in this series with extended follow-up
resumed ovarian function following chemotherapy. Previous studies
have shown post-treatment pregnancy rates of 75% to 100% among
women attempting conception after receiving bleomycin, etoposide
and cisplatin (BEP) in conjunction with fertility-sparing surgery for
ovarian cancer (Weinberg et al., 2011). However, cyclophosphamide
and doxorubicin may have signiﬁcant effects and the long-term out-
comes of VPBCAE on future fertility remain unknown.
There is currently no standard approach to managing ovarian
small-cell carcinoma of the hypercalcemic type. The rarity of this dis-
ease has precluded the development of an established ﬁrst-line che-
motherapeutic regimen for this condition. To facilitate progression
toward a more consistent standard of care for this rare gynecologic
tumor, additional cases and case series should continue to be reported.
In addition, an accessible and frequently updated case registry may
serve patients and their providers with the best hope in developing
the most optimal treatment for ovarian small-cell carcinoma of the
hypercalcemic type.
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